News
What's Going On With Pfizer Stock On Thursday?
25 Apr 24
Biotech, Large Cap, News, Health Care, Legal, Top Stories, General
Novartis Pharms Corp Gets FDA New Drug Application Approval For VIJOICE
25 Apr 24
Biotech, News, FDA, General
BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $116
24 Apr 24
News, Price Target, Analyst Ratings
Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
24 Apr 24
Biotech, Large Cap, News, Health Care, General
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
23 Apr 24
Biotech, Large Cap, News, Health Care, FDA, Top Stories, Movers, General
Novartis Radioligand Therapy Lutathera FDA Approved First Medicine Specifically For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
23 Apr 24
Biotech, News, FDA, General
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
23 Apr 24
Cryptocurrency, Large Cap, Macro Notification, Market Summary, Broad U.S. Equity ETFs, Commodities, Econ #s, Top Stories, Intraday Update, Tech, ETFs
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
23 Apr 24
Biotech, Earnings, Large Cap, News, Guidance, Health Care, Top Stories, Movers, General
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
23 Apr 24
Earnings, Equities, News, Futures, Previews, Top Stories, Economics, Federal Reserve, Pre-Market Outlook, Markets, Movers, Trading Ideas
Novartis Q1 2024 Adj EPS $1.80 Beats $1.67 Estimate, Sales $11.829B Beat $11.433B Estimate
23 Apr 24
Earnings, Earnings Beats, News
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
21 Apr 24
Analyst Color, Equities, News, Top Stories, Tech, Trading Ideas
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
19 Apr 24
Biotech, Large Cap, News, Penny Stocks, Health Care, FDA, General
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
17 Apr 24
Biotech, Large Cap, News, Health Care, General
Novartis Announced Earlier, Continuous Kesimpta Treatment For Up To Six Years Showed Sustained Efficacy In Recently Diagnosed (≤3 Years) Treatment-naïve People Living With Relapsing Multiple Sclerosis In Analysis Of Alithios Open-label Extension Study
17 Apr 24
News
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
16 Apr 24
Analyst Color, Biotech, Equities, News, Upgrades, Health Care, Price Target, Analyst Ratings, Movers, Trading Ideas, General
MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per Share
15 Apr 24
M&A
Novartis Fabhalta Data Show Clinically Meaningful And Statistically Significant Proteinuria Reduction Of 38.3% Versus Placebo For Patients With IgA Nephropathy
15 Apr 24
Biotech, News, General
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
11 Apr 24
Analyst Color, Biotech, Equities, Large Cap, M&A, News, Upgrades, Health Care, Price Target, Analyst Ratings, Trading Ideas, General
Looking At Novartis's Recent Unusual Options Activity
11 Apr 24
Options, Markets
Arvinas Enters Exclusive Strategic License Agreement With Novartis; Arvinas To Receive $150M Upfront Payment & Up To $1.01B In Milestones
11 Apr 24
News, Contracts
Press releases
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
15 Apr 24
Press Releases
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 Apr 24
News, Contracts, Press Releases
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
6 Apr 24
Press Releases
Biotech's Role in Addressing the Pancreatic Cancer Emergency
14 Mar 24
Small Cap, Opinion, Press Releases